This notice provides interested stakeholders with the opportunity
to provide comments on Health Canada's proposal for the exclusion of barbituric acid,
naloxegol and its salts, methylnaltrexone and its salts, as well as the salts of nalmefene,
naloxone and naltrexone from the schedules to the CDSA and its regulations. This proposal
also includes amendments to Part J of the Food and Drug Regulations (FDR) in order to
add Catha edulis Forsk, cathine and cathinone in its schedule.